March 2017: Better PrEParation needed?

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss some of the implications related to funding of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV). They consider the Court of Appeal decision on funding and the role of clinical and health economic evaluations for preventative treatments. Full article available here: http://dtb.bmj.com/content/55/3/25. The editors also review the evidence for a new formulation of desmopressin for nocturia in adults (http://dtb.bmj.com/content/55/3/30) and discuss penicillin allergy (http://dtb.bmj.com/content/55/3/33). Find out more about the March issue here: http://dtb.bmj.com/content/55/3/26.

Om Podcasten

The Drug and Therapeutics Bulletin (DTB) Podcast is your source for practical, independent, and evidence-based information on drugs, medication, and prescribing. Join the Editor-in-Chief and Deputy Editor of DTB each month as they discuss the key highlights of the latest issue. DTB - dtb.bmj.com - is published by BMJ Group, and offers rigorous, independent evaluations and practical advice on treatments and disease management for doctors, pharmacists, and healthcare professionals. Subscribe to the DTB Podcast and get the latest drug and therapeutic insights. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.